STOCK TITAN

Hologic Inc - HOLX STOCK NEWS

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.

Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.

Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.

Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.

Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.

Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) will showcase its breast and skeletal health innovations at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 28 to Dec. 2 at McCormick Place, booth #2511. The event features hands-on experiences with various products, including the Dimensions® mammography portfolio and Mach™ ultrasound systems.

Attendees can participate in CME and non-CME medical education sessions, discussing advanced topics like 3D-guided biopsies and AI in breast imaging.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 4th Annual Evercore ISI HealthCONx Conference on November 30 at 9:40 a.m. Eastern Time. The presentation will be accessible via a link on Hologic’s investors page, and the webcast will be available for 30 days post-event. Hologic is dedicated to enhancing women’s health and well-being through innovative medical technologies for early detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (Nasdaq: HOLX) has launched its innovative Genius™ Digital Diagnostics System in Europe, enhancing cervical cancer screening with artificial intelligence and advanced imaging. This system aims to identify pre-cancerous lesions and cervical cancer cells more effectively. The Genius system is designed to improve lab efficiency and workflow while promoting collaboration among laboratories. Customer feedback has been overwhelmingly positive, highlighting its potential to transform screening processes and enhance patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) is set to launch the NovaSure® V5 global endometrial ablation device at the AAGL 50th Global Congress (November 14-17). This innovative device, building on a 20-year legacy of the NovaSure system, aims to enhance the physician experience. With over 3 million treatments performed since its FDA approval in 2001, the device incorporates advanced features like the EndoForm™ cervical seal technology and SureClear™ fluid removal system. The launch reflects Hologic's commitment to improving outcomes for women and providing physicians with reliable tools.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (HOLX) reported a fiscal Q4 2021 revenue of $1.317 billion, slightly below last year but exceeding expectations. GAAP diluted EPS was $1.28, down 31.9% year-over-year, while non-GAAP diluted EPS was $1.61, down 22.2%. The company anticipates solid growth in core women's health businesses for fiscal 2022, projecting revenues of $3.750B to $4.000B. Key highlights include a 47% annual revenue growth driven by women's health and COVID-19 testing, although COVID-19 assay sales decreased substantially. Strong operational cash flow of $465.4 million was reported for Q4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary

Hologic, Inc. has launched the Aptima® SARS-CoV-2/Flu Assay for simultaneous detection of SARS-CoV-2, influenza A, and influenza B. The assay, CE-Marked for Europe and FDA authorized, provides results in approximately three hours and can process over 1,000 tests daily. This multiplex test addresses the overlap of symptoms between these viruses, enhancing testing options as the flu season approaches. Hologic has distributed over 100 million SARS-CoV-2 assays globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
covid-19
Rhea-AI Summary

Hologic, Inc. has partnered with Mediflix to release Carolina, a documentary-style film highlighting the breast cancer journey. Launched during Breast Cancer Awareness Month, this film guides patients from diagnosis to reconstruction. Featuring testimonials from survivors and experts, Carolina aims to enhance understanding of minimally invasive surgical options, such as the Reconstructive Lumpectomy. This innovative approach uses Hologic’s BioZorb marker to improve cosmetic outcomes post-surgery, addressing the emotional concerns of patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary

Black Women’s Health Imperative and Hologic hosted a roundtable, Unmuting Fibroids: Getting Loud for Equal Care, addressing disparities in uterine fibroid care. Experts emphasized that understanding menstruation as a vital health sign is crucial for prioritizing care. Uterine fibroids affect 80% of Black women, leading to severe health implications. Key initiatives include improving education for healthcare providers, advocating for funding legislation, and promoting culturally competent care to reduce disparities. Hologic supports this through its Project Health Equality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) has announced the acquisition of Bolder Surgical for approximately $160 million. This strategic move aims to diversify Hologic's surgical portfolio by adding advanced vessel sealing devices. Bolder's products are expected to enhance surgical efficiency, particularly in OB/GYN applications, capitalizing on a larger market potential. The acquisition is forecasted to generate $10 million in revenue this year and is expected to be slightly dilutive to earnings in fiscal 2022, with a break-even outlook for fiscal 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2021 financial results on Monday, November 1, after market close. A conference call hosted by management will take place at 4:30 p.m. ET. Interested participants can join by calling 800-458-4121 (US/Canada) or +1 323-794-2093 (international) with access code 2820462. A replay will be available post-call through December 1, 2021. Additionally, the call will be accessible via a live webcast on the company’s website at www.investors.hologic.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags

FAQ

What is the current stock price of Hologic (HOLX)?

The current stock price of Hologic (HOLX) is $71.65 as of December 20, 2024.

What is the market cap of Hologic (HOLX)?

The market cap of Hologic (HOLX) is approximately 16.1B.

What does Hologic Inc. specialize in?

Hologic Inc. specializes in developing, marketing, and servicing innovative and accurate diagnostic imaging systems and surgical products, with a focus on women's healthcare.

Where is Hologic Inc. headquartered?

Hologic Inc. is headquartered in Bedford, Massachusetts.

What are the main segments of Hologic’s business?

Hologic operates in five main segments: diagnostics, breast health, surgical, and skeletal health.

Which segment contributes the most to Hologic's revenue?

The diagnostics segment contributes the most, accounting for 60% of Hologic's total sales.

How has the pandemic affected Hologic’s business segments?

The pandemic boosted the diagnostics segment but initially suppressed the breast health segment.

What percentage of Hologic’s revenue comes from the United States?

69% of Hologic’s revenue comes from the United States.

How did the acquisition of Gen-Probe impact Hologic?

The acquisition of Gen-Probe shifted Hologic’s focus more towards commercial diagnostics.

How can I stay updated with Hologic's latest news?

You can stay updated by visiting Hologic's website, or following them on Facebook and Twitter.

What is Hologic’s approach to healthcare?

Hologic is dedicated to the science of sure, providing greater confidence and peace of mind in medical diagnosis to enable healthier lives.

What percentage of Hologic’s revenue comes from international markets?

Approximately 31% of Hologic’s revenue comes from international markets, including Europe, Asia, and other regions.

Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

16.11B
225.10M
0.8%
105.31%
1.98%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
MARLBOROUGH